Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

Hanmi Pharmaceutical Company Limited230 enrolled

Overview

The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

230

Conditions

Hypertension Hyperlipidemia

Interventions

Irbesartan/Atorvastatin ADRUG

once daily, P.O. 8week

IrbesartanDRUG

once daily, P.O. 8week

Atorvastatin ADRUG

once daily, P.O. 8week

Placebo

Eligibility

Sex: ALLMin age: 19 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged between 19 and 75 years * Signed informed consent Exclusion Criteria: * At screening, SPB ≥ 180mmHg or DBP ≥ 110mmHg or LDL-C \> 250mg/dL or TG ≥ 400mg/dL * Has a history of hypersensitivity to Angiotensin Ⅱ receptor blocker or HMG-CoA reductase inhibitor or component of this drug * Has a history of multi-drug allergy

Locations (1)

16 institutions including Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Percent change from baseline to 8 week in LDL-Cholesterol

Time frame: baseline and 8 week

Change from baseline to 8 week in Blood Pressure.

Time frame: baseline and 8 week

Secondary Outcomes

Percentage of patients reaching treatment goals according to NCEP ATP III Guideline and Blood pressure responder rate according to JNC VII Guideline.

Time frame: week 8

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.